Clinical trial
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III…
NCT00003641 · ECOG-ACRIN Cancer Research Group, Other · Active, not recruiting
Key facts
| NCT number | NCT00003641 |
|---|---|
| Title | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma |
| Official title | Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma |
| Lead sponsor | ECOG-ACRIN Cancer Research Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH SWOG Cancer Research Network Cancer and Leukemia Group B NCIC Clinical Trials Group Children's Oncology Group |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Other |
| Interventions | interferon alfa-2b, observation |
| Enrollment | 1,150 |
| Start date | Mar 25, 1999 |
| Primary completion | Jan 1, 2015 |
| Completion | Dec 1, 2025 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 18, 2025 |
| Countries | Australia, Canada, South Africa, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: